I'd presume Roche will now spend 9-12mths on pre-clinical trials.
In the case of an active drug lead, in-vitro(test tube) and in-vivo(animal testing) are conducted. If results satisfy Roche, milestone payments would flow and clinical trials(human) will then go ahead.
I'm not sure what trials would be carried out if the peptide is a passive carrier.
Whether PYCs peptide is an active drug lead or a carrier for an active molecule, toxicology tests would show any adverse effects.
Hard to know what has already been done. Would be nice to get more detail.
Numerator: you're more knowledgeable, can you add to this?
ST
roche deal, page-6
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $793.2M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.0¢ | $537.4K | 3.013M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 240589 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 76524 | 2 |
View Market Depth
| Last trade - 16.10pm 30/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |